TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from MapLight Therapeutics, Inc. ( (MPLT) ).
MapLight Therapeutics reported its third-quarter 2025 financial results, highlighting significant progress in its clinical trials and financial stability. The company completed an initial public offering and private placement in October 2025, raising $296.5 million, which will fund operations through 2027. Key developments include the initiation of Phase 2 trials for ML-007C-MA for schizophrenia and Alzheimer’s disease psychosis, with results expected in 2026 and 2027 respectively, and the completion of enrollment in the IRIS Phase 2 study for autism spectrum disorder. The company ended the quarter with $227.2 million in cash, cash equivalents, and short-term investments, despite a net loss of $29.4 million.
The most recent analyst rating on (MPLT) stock is a Buy with a $28.00 price target. To see the full list of analyst forecasts on MapLight Therapeutics, Inc. stock, see the MPLT Stock Forecast page.
More about MapLight Therapeutics, Inc.
MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders. The company was founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients.
Average Trading Volume: 389,147
For detailed information about MPLT stock, go to TipRanks’ Stock Analysis page.